With a shortage of insulin products in the United States, our diabetic patients are left without lifesaving medications, making this a prominent barrier in clinical practice. However, insulin biosimilars may offer more accessibility and affordability, but what do we know about them? Join Dr. Mary Katherine Cheeley as she speaks with Dr. Lizzie Cook, Clinical Pharmacist at Robert J. Dole Veteran Affairs Medical Center in Wichita, Kansas.